Perspective Therapeutics (NYSE:CATX) Shares Gap Down - What's Next?

Shares of Perspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) gapped down prior to trading on Friday . The stock had previously closed at $13.25, but opened at $11.50. Perspective Therapeutics shares last traded at $9.87, with a volume of 639,119 shares changing hands.

Wall Street Analysts Forecast Growth

CATX has been the topic of several research reports. Truist Financial initiated coverage on shares of Perspective Therapeutics in a research report on Wednesday, September 25th. They issued a "buy" rating and a $21.00 price target on the stock. Wedbush began coverage on shares of Perspective Therapeutics in a research report on Tuesday, October 1st. They set an "outperform" rating and a $25.00 target price on the stock. Cantor Fitzgerald restated an "overweight" rating on shares of Perspective Therapeutics in a research report on Monday, September 9th. Royal Bank of Canada decreased their target price on shares of Perspective Therapeutics from $29.00 to $27.00 and set an "outperform" rating on the stock in a research report on Friday, August 16th. Finally, Oppenheimer restated an "outperform" rating and set a $22.00 target price on shares of Perspective Therapeutics in a research report on Friday. Eight analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $21.43.

Perspective Therapeutics Trading Down 4.8 %

The company's fifty day simple moving average is $13.81.

Perspective Therapeutics (NYSE:CATX - Get Free Report) last issued its earnings results on Monday, August 12th. The company reported ($0.17) EPS for the quarter, beating analysts' consensus estimates of ($0.21) by $0.04. The business had revenue of $0.53 million during the quarter. On average, research analysts expect that Perspective Therapeutics, Inc. will post -0.87 earnings per share for the current year.

Hedge Funds Weigh In On Perspective Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. increased its stake in Perspective Therapeutics by 34.6% during the 1st quarter. Vanguard Group Inc. now owns 17,780,106 shares of the company's stock worth $21,158,000 after buying an additional 4,566,356 shares during the period. Janus Henderson Group PLC purchased a new stake in Perspective Therapeutics during the 1st quarter worth $15,511,000. Affinity Asset Advisors LLC purchased a new stake in Perspective Therapeutics during the 1st quarter worth $6,069,000. Ally Bridge Group NY LLC purchased a new stake in Perspective Therapeutics during the 2nd quarter worth $3,951,000. Finally, WealthPLAN Partners LLC purchased a new stake in Perspective Therapeutics during the 2nd quarter worth $1,695,000. Hedge funds and other institutional investors own 54.66% of the company's stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.